Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
NLG-802 by Lumos Pharma for Glioblastoma Multiforme (GBM): Likelihood of Approval
NLG-802 is under clinical development by Lumos Pharma and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...